Unsere Publikationen

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients

Link
https://doi.org/10.1177/2045894019872192
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Lerche M, Eichstaedt CA, Hinderhofer K, Grünig E, Tausche K, Ziemssen T, Halank M, Wirtz H, Seyfarth HJ.
Verlag
Pulm Circ. 2019 Nov 18;9(3):2045894019872192.
Zum Eintrag

Early central vs. peripheral immunological and neurobiological effects of fingolimod—a longitudinal study

Link
https://doi.org/10.1007/s00109-019-01812-x
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Sehr T, Akgün K, Proschmann U, Bucki R, Zendzian-Piotrowska M, Ziemssen T.
Verlag
J Mol Med 2019;97(9):1263-1271.
Zum Eintrag

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

Link
https://doi.org/10.1007/s13311-017-0595-y
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group.
Verlag
Neurotherapeutics. 2018 Jan;15(1):190-199.
Zum Eintrag

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis

Link
https://doi.org/10.1177/1756286418759895
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Akgün K, Metz I, Kitzler HH, Brück W, Ziemssen T.
Verlag
Ther Adv Neurol Disord 2018;11.
Zum Eintrag

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

Link
https://doi.org/10.1177/1756286418803248
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.
Verlag
Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248.
Zum Eintrag

Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod

Link
https://doi.org/10.1002/cpdd.424
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
David OJ, Berwick A, Pezous N, Lang M, Tiel-Wilck K, Ziemssen T, Li P, Hara H, Schmouder R.
Verlag
Clin Pharmacol Drug Dev. 2018 Feb;7(2):217-221.
Zum Eintrag

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Link
https://doi.org/10.1016/s0140-6736(18)30475-6
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.
Verlag
Lancet. 2018 Mar 31;391(10127):1263-1273. Epub 2018 Mar 23.
Zum Eintrag

Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing"

Link
https://doi.org/10.1177/1352458517726384
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Sehr T, Proschmann U, Thomas K, Ziemssen T.
Verlag
Mult Scler J 2018;24(6):820-822.
Zum Eintrag
9 10 11 12 13

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-